Monnereau A. National estimate of the incidence of cancer in France between 1980 and 2012: a study based on Francim network of cancer registries, part 2 - hematological malignancies. Available at: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2013/Estimation-nationale-de-l-incidence-des-cancers-en-France-entre-1980-et-2012. Accessed: March 18, 2014.
Projection de l'incidence et de la mortalité par cancer en France en 2010. Available at: http://www.invs.sante.fr/applications/cancers/projections2010/rapport-projections-nationales-cancer-2010.pdf. Accessed: March 19, 2014.
Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX
A.W. Pawluczkowycz, F.J. Beurskens, and P.V. Beum Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX J Immunol 183 2009 749 758
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy
L. Bologna, E. Gotti, and F. Da Roit Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy J Immunol 190 2013 231 239
The European Medicines Agency review of ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: Summary of the scientific assessment of the European Medicines Agency Committee for Medicinal Products for Human Use
I. Gravanis, J. Ersbøll, E. Skovlund, E. Abadie, M. Marty, and F. Pignatti The European Medicines Agency review of ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European Medicines Agency Committee for Medicinal Products for Human Use Oncologist 15 2010 1335 1343
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
M. Hallek, B.D. Cheson, and D. Catovsky Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
B. Coiffier, S. Lepretre, and L.M. Pedersen Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study Blood 111 2008 1094 1100
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
W.G. Wierda, T.J. Kipps, and J. Mayer Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 28 2010 1749 1755
Arzerra: summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001131/WC500093091.pdf.
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study
W.G. Wierda, S. Padmanabhan, G.W. Chan, I.V. Gupta, S. Lisby, and A. Osterborg Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study Blood 118 2011 5126 5129
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p
K. Namberger, L. Weiss, B. Krause, T. Melchardt, and R. Greil A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p Eur J Haematol 90 2013 349 350
Ofatumumab in advanced stage chronic lymphocytic leukaemia: Results of the UK named patient compassionate use programme
O. Chowdhury, A. Varghese, and J. Pattinson Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme Br J Haematol 155 2011 519 521
